Pfizer Mulls Strategic Options For Some Early-Stage Rare Disease Candidates - Pfizer (NYSE:PFE)

Pfizer Inc PFE is reportedly exploring options for some early-stage candidates for rare diseases, including developing new viral-based gene therapies.
Financial newspaper Barron's first reported on Thursday.
The U.S. pharma giant said these options included collaborations with other drug developers for these medicines or establishing a new company, with an aim to focus on "high-impact" medicines and vaccines.
Also see: Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry.
The company said it would look for external opportunities for most of its early-stage rare disease programs in neurology, cardiology, and gene therapy programs not yet in clinical trials.
Pfizer might chop its gene therapy manufacturing facility in Durham, North Carolina, with the decision. The company announced in December 2021 that it was investing nearly $70 million.
Pfizer plans to focus on internally developing rare disease treatments using technologies such as gene editing, Reuters wrote citing Barron's report.
Earlier today, the FDA accepted Pfizer's supplemental application for its 20-valent pneumococcal conjugate vaccine candidate for infants and children six weeks through 17 years.
Pfizer in August 2022 announced a $4.5 billion deal for sickle cell disease drugmaker Global Blood Therapeutics months after its $11.6 billion deal for Biohaven Pharmaceutical Holding.
Price Action: PFE shares are down 0.12% at $49.60 during the premarket session on the last check Friday.

Market News and Data brought to you by Benzinga APIs